Ascendis Pharma Iberia enters Portugal

The pharmaceutical company Ascendis Pharma has entered the Portuguese market with a focus on rare endocrine diseases.

The move is part of the company’s Iberian strategy and its objective of contributing positively to the Portuguese healthcare system.

The opening of the new office in Lisbon follows the inauguration of the Iberian headquarters in Madrid in 2024.

Founded in 2007 and headquartered in Copenhagen, Denmark, parent company Ascendis Pharma A/S is a global biopharmaceutical company dedicated to making a significant difference in patients’ lives.

The company has been publicly traded since 2007 and has more than 1,100 employees worldwide, with operations in Europe and the United States.

“It is both a source of pride and a very relevant goal to build, launch and lead a new team dedicated to meeting the needs of patients with rare endocrine diseases in Portugal.

Our first priority – already underway – is to work with local authorities to bring our treatment for chronic hypoparathyroidism, a rare, chronic and often debilitating disease with a significant impact on the health and quality of life of patients, to the Portuguese market,” says Sérgio Alves, Operations Director of Ascendis Pharma Portugal. (Pictured).

Image: Ascendis Pharma

Source: Eco Online